

Human Systems

Summary

The human system of a TENS unit involves an individual using a portable, electronically controlled medical device to manage pain. This system includes the physical device itself—designed to be wearable and ambulatory—and the user, who places electrodes on their skin and adjusts stimulation settings to find relief (St. Louis and Caparso). This user-controlled approach allows for personalized therapy, but the interaction also extends to how the user's own central nervous system processes and modulates pain, a complex process that can be influenced by brain activity even before the pain signal is consciously perceived (Vance et al.).

Explanation

From a human systems perspective, the TENS unit is a tangible, self-administered therapy. The patent for a TENS device outlines its design as a wearable system with a power source, a controller, and electrodes, intended to be used while the person goes about their daily activities (St. Louis and Caparso). The core of this system is the interaction between the user and the device: the individual is responsible for placing the electrodes and adjusting the stimulation intensity to a level that is strong but not painful.

The study on tDCS adds another layer to this human system by highlighting the importance of the brain's own top-down control over pain, known as conditioned pain modulation (CPM). This research shows that brain stimulation can enhance the body's natural ability to inhibit pain (Vance et al.). This implies that the effectiveness of any pain relief therapy, including TENS, is not just about the device itself but also about the individual's unique central nervous system state and its capacity to suppress pain signals.

Biological Systems

Summary

The biological system of a TENS unit operates by using electrical pulses to interact with the body's nervous system at multiple levels. Primarily, it stimulates large sensory nerves in the periphery to "close the gate" on pain signals, as described by the gate control theory. It also triggers the release of the body's own opioid-like chemicals, although this can lead to the body developing tolerance over time (Vera-Portocarrero et al.). Furthermore, the ultimate perception of pain is modulated by descending pathways from the brain, which can be influenced by factors like expectation and other sensory inputs (Vance et al.).

Explanation

Biologically, a TENS unit works by sending electrical currents through the skin to activate underlying nerves. The foundational mechanism is the gate control theory of pain, where the stimulation of large-diameter A β nerve fibers (which carry touch and pressure sensations) inhibits the transmission of pain signals from smaller A δ and C-fibers at the spinal cord level.

The animal study by Vera-Portocarrero et al. confirms that TENS also engages the body's endogenous opioid system, triggering the release of natural pain-relieving chemicals. However, this study crucially demonstrates that this can lead to tolerance, where the pain-relieving effect diminishes with repeated use, particularly in models of inflammatory pain. Their research also found TENS to be minimally effective for neuropathic pain, suggesting its biological impact is highly dependent on the type of pain.

Finally, the tDCS study illustrates that pain processing is not just a one-way street from the periphery to the brain. The brain has its own powerful descending pain modulation pathways, which can inhibit incoming pain signals. The study showed that enhancing activity in the motor cortex could improve this natural pain-inhibition system (Vance et al.). This suggests that the biological effect of a therapy like TENS is ultimately interpreted and controlled by these higher-level central nervous system processes.

Mechanical Systems

Summary

The mechanical system of a TENS unit is a rather interesting case, as the units do not have a “mechanical system” like most people would imagine, rather they have an electro-mechanical system that specifically refers to the physical mechanical components that deliver the electrical therapy to the body. In this case, the pure mechanical system would refer to the housing and organization of the different parts within the unit, as while the internal electronics generate perform the therapy, the housing and organization allow the TENS unit to function safely, effectively, and be usable by the patient.

Explanation

Mechanically, a TENS unit is made up of two parts: the housing of the unit, and the organization of the physical aspects of the unit. Let's start with the housing of the unit. The housing of the unit needs to be strong and sturdy enough to protect the fragile internal components, such as the delicate printed circuit board (PCB), pulse generator, battery, and various wiring. The housing protects the device from impacts, dust and debris, and

pressure that could damage sensitive internal components. The housing also protects the user just as much as it protects the device, primarily by protecting the user from being exposed to uncontrolled electrical shocks, as the housing is typically made from a moisture-resistant, non-conductive material, usually medical-grade ABS (Acrylonitrile Butadiene Styrene) plastic. Due to the TENS unit being a portable medical device, the housing is built to be very durable and long-lasting as it needs to withstand daily use, wear and tear, and potential accidents. On the other hand, the housing also needs to be ergonomic and portable, preferably comfortable to carry in one hand while also being lightweight and relatively small. Moving on to the organization, the TENS unit was built around ease of use, accessibility, safety, and intuitive operation. All of which are imperative to the day-to-day function and human interfacing (the human systems section goes more in depth on this).

Electrical Systems

Summary

The electrical system of a TENS unit involves taking a complicated battery-powered pulse generator and taking the simple, low-voltage DC power from the batteries and converting it into controlled, high-voltage, low-current electrical pulses that interact with the nervous system. The resulting high-voltage electrical pulses from the system allow the TENS unit to properly interact with the nervous system while the fact that the pulses are low-current keeps the pulses from causing damage to the skin and nervous tissues.

Explanation

Electrically, the TENS unit works by drawing the raw low-voltage DC power from the power source (usually AA, AAA, or rechargeable lithium-ion batteries), which is only enough to run the rest of the electronics, and it not enough to interact with the human body on its own. The next step is for the user to interact with the microcontroller (MCU) that is connected to the user interface of buttons, dials, and an LCD screen that based on the inputted settings, the MCU's internal oscillator begins to generate a precise, low-voltage digital signal pattern. This signal from the MCU goes to a set of pulse-shaping circuitry to take the basic square wave that the MCU outputs and modifies it into (most commonly) a biphasic waveform. A biphasic waveform is the most common and safest waveform for this, and has a positive phase followed by an equal negative phase. This shaped, low-voltage signal is then fed into a tiny step-up transformer that uses two coils of wire to change the input voltage of roughly 3-9 volts, to an output voltage of up to 100-150 volts. This low-amperage, high-voltage signal then exits the transformer and is sent to the output jacks where the lead

wires carry this pulse from the unit to the electrodes, then the electrodes transfer the signal through a layer of conductive gel to the skin and sensory nerves underneath.

Chemical Systems

Summary

The chemical system of a TENS unit is centered on the materials that directly interface with the user's skin: the conductive gel and the adhesive used on the electrodes. This system's primary input is the application of these chemical compounds to the skin. The main output is the **facilitation of ion transfer** between the electrode and the nervous system, which allows the electrical stimulation to occur (Celestin et al.). A key chemical constraint is the need for high biocompatibility to avoid secondary outputs like irritant contact dermatitis or allergic reactions from leachable chemicals in the materials (Chatterjee and Inbarani). Furthermore, the chemical stability of these components is limited, as interactions with the skin's oils and sweat lead to degradation of the gel and adhesive over time, impacting performance and reusability (Lib-It and Ziv-Av).

Explanation


From a chemical perspective, a TENS unit cannot function without the specific materials that create a safe and effective bridge between its electrical components and the user's biological system. The explanation of this system can be broken down by its key chemical components.

1. **Electrode Gel Chemistry:** The most critical chemical component is the conductive medium, which is traditionally a hydrogel. This gel is a complex polymer network saturated with water and an electrolyte solution, most commonly potassium chloride (KCl). Its primary function is to lower the skin's naturally high electrical resistance (impedance). It achieves this by providing a reservoir of mobile K⁺ and Cl⁻ ions that carry the current from the electrode's surface, through the resistive outer layer of the skin (stratum corneum), to the target sensory nerves. The specific chemical formulation of this hydrogel is an active area of research, as it directly dictates the user's tolerance to the stimulation and overall skin health during

therapy (Celestin et al.). An improperly formulated gel can fail to provide uniform current distribution, creating "hot spots" that can cause electrical burns or pain.

2. **Adhesive Chemistry:** The second key component is the medical-grade adhesive that secures the electrode. These are typically acrylic or hydrocolloid-based adhesives designed for skin compatibility (Chatterjee and Inbarani). The chemical design is a significant challenge, balancing adhesion with atraumatic removal. A crucial chemical property is the **Moisture Vapor Transmission Rate (MVTR)**, which must be high enough to allow underlying skin to breathe and prevent moisture buildup, which can lead to skin maceration and adhesive failure (Chatterjee and Inbarani). Furthermore, the adhesive must be chemically stable, with low levels of "leachables"—residual monomers or additives from the manufacturing process that could seep out and cause skin irritation. The interaction with skin lipids (oils) is a major constraint, as these oils can plasticize the adhesive, weakening its bond and limiting the number of times an electrode can be reused (Lib-It and Ziv-Av).
3. **Chemical Degradation and Future Directions:** A major unresolved problem is the limited chemical stability and reusability of the entire electrode assembly. The patent from Lib-It and Ziv-Av describes how the hydrogel can dry out with exposure to air, while the adhesive layer becomes fouled by skin cells and oils, both of which degrade the electrode's performance. This limited lifespan creates recurring costs and waste. This challenge is driving research away from traditional wet chemistry hydrogels and towards **dry electrodes**. These next-generation electrodes use materials like silver/silver-chloride (Ag/AgCl) that can be applied directly to the skin without a gel medium (Al-Solihat et al.). Developing such a dry, flexible, and biocompatible electrode that maintains stable contact and conductivity over long-term use is a primary goal in advancing TENS technology, as it would eliminate the mess and chemical instability inherent in hydrogel-based systems (Al-Solihat et al.).

Systems and Interaction Diagram:



Gaps in Knowledge and Unresolved Problems

Our comprehensive review of the TENS device system reveals several critical gaps in knowledge and unresolved problems that span multiple domains. A primary gap exists at the intersection of the chemical and biological systems: the **long-term dermatological impact of electrode materials**. While short-term biocompatibility is a focus, there is a lack of research on the cumulative effects of daily, prolonged exposure to the chemical cocktails found in conductive gels and medical adhesives (Chatterjee and Inbarani). The mechanisms by which these chemicals interact with the skin's microbiome and barrier function over months or years are not well understood.

Furthermore, the chemical degradation of electrodes when exposed to the variable and harsh environment of the human skin—with its sweat, oils, and constant friction—is not fully characterized. This leads to inconsistent performance, where an electrode's conductivity and adhesion can change unpredictably, a problem noted in patents aiming to improve electrode design (Lib-It and Ziv-Av). This directly feeds into a major unresolved problem from a biological and human systems perspective: **therapeutic inconsistency and the development of tolerance**. The animal study by Vera-Portocarrero et al. highlights that TENS effectiveness is highly dependent on the type of pain (e.g., inflammatory vs. neuropathic) and that tolerance can develop, diminishing the analgesic effect. It remains an open question how much of this tolerance is a central nervous system phenomenon versus a peripheral issue caused by degrading electrode-skin interface quality.

Ultimately, these issues converge on the largest unresolved problem: creating an electrode that is truly **"wear and forget."** Such a device would need to maintain perfect adhesion and stable conductivity for extended periods (days or even weeks) without causing skin irritation, breaking down chemically, or losing effectiveness (Al-Solihat et al.). Solving this would require a new generation of materials that are not only biocompatible and conductive but also resilient to the dynamic biological environment of the skin.

How This Literature Informs Our Design Direction

This comprehensive literature review provides a powerful, evidence-based foundation for our group's design direction. The analysis across the five domains illuminates a central, unifying theme: the primary barrier to effective, long-term TENS therapy is the cumbersome and impractical nature of the user interface. The literature confirms that the physical, chemical, and electrical interface between the device and the user is the source of most of its shortcomings. Therefore, our proposed design modification—integrating the TENS

system directly into a wearable garment—is not merely an incremental improvement but a direct, holistic response to the specific problems identified in our research.

- From the **Human and Mechanical Systems** perspective, a garment-based system directly solves the core usability problems of managing unwieldy wires, placing electrodes correctly, and carrying a bulky, separate controller. It addresses the need for a truly ambulatory and ergonomic system that doesn't interfere with daily life, a key consideration in the original patent design (St. Louis and Caparso).
- From the **Biological and Electrical Systems** perspective, integrating electrodes into a garment using conductive textiles (Li et al.) ensures consistent and repeatable placement on the correct dermatomes. This could significantly improve therapeutic consistency and potentially mitigate the tolerance effect by ensuring the stimulation is always delivered to the optimal nerve pathways, addressing a key variable noted in the pain modulation research (Vera-Portocarrero et al.; Vance et al.).
- From the **Chemical Systems** perspective, our design direction allows us to sidestep the most problematic components of current TENS technology. By leveraging novel textile-based or dry electrodes (Al-Solihat et al.; Li et al.), we can move away from the cycle of applying, removing, and replacing disposable hydrogel electrodes, thereby eliminating the primary source of skin irritation and chemical degradation (Chatterjee and Inbarani; Lib-It and Ziv-Av).

In conclusion, this literature provides strong evidence that our focus on an integrated, garment-based design is the most effective path forward. It allows us to propose a design modification that is not just for convenience, but one that fundamentally addresses the interconnected challenges across all five domains to create a more seamless, effective, and user-centered therapeutic experience.

Works Cited

1. Li, Li & Man, Wai & Li, Yi & Wan, Kam & Wan, Sai & Wong, Thomas. (2010). Design of Intelligent Garment with Transcutaneous Electrical Nerve Stimulation Function Based on the Intarsia Knitting Technique. *Textile Research Journal*. 80. 279-286. 10.1177/0040517509105276.
2. St. Louis, Kevin, and Anthony V. Caparso. *Implantable Pulse Generator and Method for Use with an Ambulatory Medical System*. U.S. Patent 8,131,374 B2, filed 20 Apr. 2007, and issued 6 Mar. 2012.

3. Vance, C.G.T., et al. "Active-tDCS Applied to the Motor Cortex and Conditioned Pain Modulation in Healthy Individuals." *Neuroscience Letters*, vol. 705, 15 July 2019, pp. 200-06. *ScienceDirect*, doi:10.1016/j.neulet.2019.04.041.
4. Vera-Portocarrero, Louis P., et al. "Differential Effects of Subcutaneous vs. Transcutaneous Electrical Stimulation in Rodent Models of Inflammatory and Neuropathic Pain." *Pain Medicine*, vol. 15, no. 1, Jan. 2014, pp. 117-31. *ScienceDirect*, doi:10.1111/pme.12276.
5. Al-Solihat, Khaled M., et al. "Development of Novel, Flexible, and Biocompatible Ag/AgCl Dry Electrodes for Long-Term ECG Monitoring." *Sensors*, vol. 20, no. 15, 2020, p. 4104. *MDPI*, doi:10.3390/s20154104.
6. Celestin, M M, et al. "Effects of a Novel Conductive Hydrogel on Skin Health and Electrostimulation Tolerance." *Journal of Pain*, vol. 14, no. 4, 2013, p. S73. *ScienceDirect*, doi:10.1016/j.jpain.2013.01.300.
7. Chatterjee, L. A., and P. G. Inbarani. "A Review on Skin-Compatible Medical Adhesives." *Journal of Adhesion Science and Technology*, vol. 33, no. 16, 2019, pp. 1735-1759. *Taylor & Francis Online*, doi:10.1080/01694243.2019.1614742.
8. Lib-It, David, and Ziv-Av, Amotz. *Transcutaneous Electrical Nerve Stimulator Electrode Assembly*. U.S. Patent 9,545,527 B2, filed 15 Oct. 2014, and issued 17 Jan. 2017.